SCHEMBL26112451

SCHEMBL26112451

O=C(O)CNC(=O)c1ccc2nc3ccccc3cc2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 1/20 0.57
PTPRC P08575 2/20 0.51
CTSL P07711 1/20 0.51
PTPN13 Q12923 1/20 0.51
KDM4E B2RXH2 4/20 0.46
MAPT P10636 2/20 0.46
HIF1A Q16665 1/20 0.46
SLC22A6 Q4U2R8 1/20 0.46
SLC22A8 Q8TCC7 1/20 0.46
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
MAPK1 P28482 1/20 0.46
ALDH1A1 P00352 3/20 0.45
HPGD P15428 3/20 0.45
GAA P10253 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
NR1H4 Q96RI1 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26116380 0.91 KDM4C (0.61) KDM4CPTPRCCTSLPTPN13KDM4E
SCHEMBL30572035 0.85 STAMBP (0.51) PTPRCKDM4EMAPTMAPK1ALDH1A1
SCHEMBL26118756 0.83 PTPRC (0.57) KDM4CPTPRCCTSLPTPN13KDM4E
SCHEMBL8411708 0.83 HDAC1 (0.60) KDM4EALDH1A1HPGDGAANR1H4
SCHEMBL17634217 0.83 PLK1 (0.65) MAPTALDH1A1GAAPLK1L3MBTL1
SCHEMBL5632427 0.82 NR1H4 (0.63) KDM4CPTPRCCTSLPTPN13KDM4E
SCHEMBL5309154 0.81 MGAM (0.62) KDM4CMAPT
SCHEMBL8411706 0.79 HDAC1 (0.49) KDM4EMAPTALDH1A1HPGDGAA
SCHEMBL7564725 0.79 HDAC1 (0.49) KDM4EMAPTALDH1A1HPGDGAA
SCHEMBL7565802 0.78 MGAM (0.61) KDM4EMAPTALDH1A1HPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346585-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2025-11-13 US disclosed
WO-2023183405-A2 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2023-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346585-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS C5, C1S, C9 KDM4C 4430/4885PTPRC 2222/4885CTSL 315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.